Cue Biopharma Shares Rise Sharply in Premarket Trading After Positive Phase 2 Trial Results
Cue Biopharma (NASDAQ:CUE) shares surged by 41.6% during premarket trading following the release of positive topline results from a Phase 2 clinical trial for its investigational drug CUE-221 in patients with chronic spontaneous urticaria. The study, conducted in China and led by Genesis Life Sciences, involved 145 participants whose symptoms were not adequately controlled by standard antihistamines. The treatment met both the primary endpoint and a key secondary endpoint with high statistical significance while maintaining a favorable safety profile. Although CUE-221 showed an efficacy profile distinct from omalizumab (Xolair), it has yet to demonstrate superiority over this established therapy. The results could support further development, potentially leading to a Phase 2b/3 trial aimed at supporting regulatory applications. The stock's rise also followed B. Riley Securities initiating coverage with a Buy rating and broader market gains.
Tickers: $CUE
Topics: biopharma chronic_spontaneous_urticaria CUE-221 monoclonal_antibody